Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Aug 15, 2024 4:57pm
117 Views
Post# 36181428

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Approx 3.5 million warrants expiring on August 14, 2024

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Approx 3.5 million warrants expiring on August 14, 2024If ONCY had run a Phase III trial for mBC when they were granted a SPA by FDA in 2017 (or was it 18), Pela would be approved by now...

Cash as of end of Q1 was 29 million... so there won't be any money left to run this trial unless they dilute shareholders significantly again... assuming cash of 15 million, this only values ONCY at 50 million... not much for a company on the cusp of transforming the world... still, in positive news, I fully expect an orchestrated run up in price (albeit very brief) before the reveal of the OS data... so the piggies can oink out as much stock as they can...

It's all just a little too late... after the latest fireside chat... all we got was a firesale. the market agreed it was a shambles... and pps has been under a buck for 10 days... how long before delisting concerns crop up again..??

Matt has had a relapse, Prof Heineken and his sidekick Crook Look sound dull and tired... there was zero energy, zero enthusiam, just more maybes, next year, blah blah blah... Key patent expires in 2027... if tjhey don't get accelerated approval (and it's by far and away a done deal) they won't have a product worth spending more dope money on.

wish me luck with Tesla...
<< Previous
Bullboard Posts
Next >>